According to the American Cancer Society, about 1 out of every 8 men will be diagnosed with prostate cancer during his lifetime...
Marks a departure from traditional liquid reagent-based testing methods...
Collaboration Builds upon Fujirebio Expertise in Neurodegenerative Disease Assays and Beckman Coulter’s High Sensitivity, High Throughput, Global Installed Base of Access Family of Immunoassay Analyzers...
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe. These tests are the first post-transplant monitoring NGS products to be approved under the new, more comprehensive regulation that came into force in May 2022 and confirm Devyser's two NGS products meet the established safety, efficacy, and quality requirements....
Optina Diagnostics' pioneering pivotal REPHRASE study, currently underway, is poised to revolutionize the diagnosis and management of Alzheimer's Disease (AD). This landmark study is focused on validating the novel awAIr™-Cerebral Amyloid Status (CAS) test, an innovative tool intended to provide physicians with definitive information about Alzheimer's pathology, enabling improved management of cognitive impairments....
Patient-Led Global Summit on Science, Policy, and Care Choice Drives Optimism...
Brings Delhi’s first-ever comprehensive preventive health solution called Smart Gene Plan ...
Extending high-quality testing services to patients with latest & innovative diagnostic technologies...
Aiming to reduce the number of advanced cancers in the country ...
To drive further advancements in healthcare technology and foster transformative innovation in patient care...
